98%
921
2 minutes
20
Background/objectives: Malignant ascites frequently arises in advanced cancers with peritoneal metastasis and is associated with poor outcomes. Known mechanisms include lymphatic obstruction by tumor cells, increased vascular permeability, and sodium retention via the renin-angiotensin-aldosterone system; however, the pathogenesis remains not fully understood. We investigated whether gut and bladder microbiomes correlate with malignant ascites development or progression and whether the immune microenvironment in ascitic fluid is altered.
Methods: We enrolled 66 histologically confirmed cancer patients, dividing them into malignant ascites (n = 20) and non-ascites (n = 46) groups. Stool, urine, and ascitic fluid samples were analyzed using 16S rRNA next-generation sequencing. Immune cell subsets in ascitic fluid were characterized using flow cytometry.
Results: In 19 of the 20 malignant ascites samples, the bacterial load was too low for reliable 16S rRNA sequencing, suggesting that malignant ascites is largely sterile. The overall gut microbiome diversity did not differ significantly by ascites status, although a trend emerged in patients with peritoneal metastasis, including the enrichment of class Clostridia and Gammaproteobacteria. Bladder microbiome analysis also showed no significant differences in ascites or metastasis status. Flow cytometry revealed reduced T-cell (CD3+, CD4+, CD8+) and NK cell (CD56+) populations compared to data from cirrhotic ascites.
Conclusions: Malignant ascites exhibit minimal bacterial biomass, making comprehensive microbiome analysis challenging. Although no major global changes were noted in gut and bladder microbiomes, specific taxa were linked to peritoneal metastasis. These findings highlight an immunosuppressive ascitic environment and suggest that larger-scale or multi-omics approaches may help elucidate the role of microbiota in malignant ascites.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025743 | PMC |
http://dx.doi.org/10.3390/cancers17081280 | DOI Listing |
Int J Gynaecol Obstet
September 2025
Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSCs). Stage IC is now divided into three categories: IC1 (surgical spill), IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface), and IC3 (malignant cells in the ascites or peritoneal washings).
View Article and Find Full Text PDFActa Vet Scand
September 2025
Department of Animal Sciences (DCA), Federal University of the Semi-Arid Region - UFERSA, Avenida Francisco Mota, 572, Costa e Silva, Mossoró, 59625-900, RN, Brazil.
Background: Research on cancer in wild animals provides important insights into the mechanisms of carcinogenesis. Histiocytic sarcomas comprise a rare malignant macrophage-dendritic cell lineage neoplasm in wildlife. This study reports a case of histiocytic sarcoma in the small intestine of a collared peccary (Pecari tajacu), describing its clinical, anatomopathological, and immunohistochemical aspects.
View Article and Find Full Text PDFCureus
August 2025
Paediatrics, All India Institute of Medical Sciences, Mangalagiri, Mangalagiri, IND.
Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by the accumulation of mucinous ascites and peritoneal implants, most commonly originating from appendiceal or ovarian neoplasms. Its diagnosis is often delayed due to vague and nonspecific symptoms. We report the case of a 75-year-old female who presented with diffuse abdominal pain, melena, and significant weight loss.
View Article and Find Full Text PDFOncologist
September 2025
Department of Vascular and Interventional Radiology, Mayo Clinic, Rochester, MN.
Background: Pancreatic cancer can lead to severe stenosis of the portomesenteric venous (PV/SMV) confluence due to extrinsic compression or direct invasion. This can result in venous hypertension associated with post-prandial abdominal pain, gastrointestinal bleeding, and ascites. In patients with unresectable tumors, transhepatic PV/SMV stenting has been reported, however its safety and efficacy are poorly understood.
View Article and Find Full Text PDFCancer Rep (Hoboken)
September 2025
Western Australia Gynaecological Cancer Service, King Edward Memorial Hospital, Subiaco, Western Australia, Australia.
Background: Poly-ADP ribose polymerase inhibitors have been shown to improve progression-free survival in patients with advanced high-grade epithelial non-mucinous ovarian cancers characterized by a deficiency in homologous recombination (HRD). Guidelines recommend all patients with advanced high-grade epithelial ovarian cancer undergo genomic tumor testing for HRD. Our aim was to evaluate the first year of HRD testing at the statewide Western Australia Gynecologic Cancer Service to assess factors associated with obtaining a diagnostic HRD testing result.
View Article and Find Full Text PDF